<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H1205F3A4BAB8430F82A4B80F6D9BCC80" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 5031 IH: Preserving Patient Access to Long-Term Care Pharmacies Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-08-22</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5031</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250822">August 22, 2025</action-date><action-desc><sponsor name-id="V000134">Ms. Van Duyne</sponsor> (for herself, <cosponsor name-id="S001190">Mr. Schneider</cosponsor>, <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>, <cosponsor name-id="D000629">Ms. Davids of Kansas</cosponsor>, <cosponsor name-id="J000311">Mr. Jack</cosponsor>, and <cosponsor name-id="R000305">Ms. Ross</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to temporarily provide for long-term care pharmacy supply fees in connection with the dispensing of certain drugs.</official-title></form><legis-body id="HD4718D8145FC47C0951FB47D4A684AF6" style="OLC"> 
<section id="H8915958A209A4186BD620D1602F03E97" section-type="section-one"><enum>1.</enum><header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Preserving Patient Access to Long-Term Care Pharmacies Act</short-title></quote>.</text></section> 
<section id="H3537F9410A624D5FB3BC99941D6AA76B"><enum>2.</enum><header>Long term care pharmacy supply fee</header> 
<subsection id="HFECC6678A3274714B78778C11FED57AD"><enum>(a)</enum><header>In general</header><text>Section 1860D–4(b)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-104">42 U.S.C. 1395w–104(b)(1)</external-xref>) is amended by adding at the end the following new subparagraph:</text> <quoted-block style="OLC" id="HF50AC4332F3849208BD8F26436076DB8" display-inline="no-display-inline"> <subparagraph id="H51B45A5104404C6FAE10136D902389A3"><enum>(F)</enum><header>Long-term care pharmacy supply fees</header> <clause id="H1B90FDA9395D4F6CA3588E413B1D629F"><enum>(i)</enum><header>Plan reimbursement to pharmacy</header> <subclause id="HCE5596BBB8CC4EC7A43359DCBBCB5355"><enum>(I)</enum><header>In general</header><text>For plan years 2026 and 2027, for each specified prescription dispensed by a long-term care pharmacy to an enrollee during such plan year, each PDP sponsor of a prescription drug plan and each MA organization offering an MA–PD plan shall pay such pharmacy a supply fee in an amount equal to—</text> 
<item id="HBEF75C67A1064887956F60EBFB71F3FC" commented="no"><enum>(aa)</enum><text>for plan year 2026, $30; and</text></item> <item id="H1BFED52E3410472DA397FD1D3495C65F" commented="no"><enum>(bb)</enum><text>for plan year 2027, the amount of the supply fee for the prior plan year, increased by the annual percentage increase described in section 1860D–2(b)(6).</text></item></subclause> 
<subclause id="H66CB0473F652484FBD7C4D9489C08D6B" commented="no"><enum>(II)</enum><header>Clarification</header><text display-inline="yes-display-inline">The supply fee under this subparagraph shall be paid at the same time and in addition to any other pharmacy reimbursements, including ingredient costs, dispensing fees, or other payments negotiated between the PDP sponsor or MA organization and the long-term care pharmacy, and shall not result in a reduction to such other reimbursements.</text></subclause></clause> <clause id="H2D2177FAEEBF43A794496F7F9A7369B8"><enum>(ii)</enum><header>Enforcement</header> <subclause id="H9915CE7C720C42BAB1A4A0D59FFA1D59"><enum>(I)</enum><header>Civil money penalty</header><text>The Secretary shall impose a civil money penalty on each PDP sponsor of a prescription drug plan and MA organization offering an MA–PD plan that fails to pay a supply fee for a specified prescription dispensed to an enrollee in accordance with this subparagraph for each such failure in an amount of not less than $10,000.</text></subclause> 
<subclause id="H8E31F6B560174470A55DFCD9970ED240"><enum>(II)</enum><header>Application</header><text>The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil money penalty under this clause in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a).</text></subclause> </clause> <clause id="HCA2D0F9D5ED14CC1A91F3277EC6ACC7D"><enum>(iii)</enum><header>Definitions</header><text>In this subparagraph:</text> 
<subclause id="H294B5DD148DC4D3D947088880E231881"><enum>(I)</enum><header>Applicable maximum fair price eligible individual</header><text>The term <term>applicable maximum fair price eligible individual</term> means, with respect to a specified prescription, a maximum fair price eligible individual who, with respect to such prescription, is described in section 1191(c)(2)(A).</text></subclause> <subclause id="HEE07E9D01B6E42F2BFC55063ADB47732"><enum>(II)</enum><header>Long-term care pharmacy</header><text>The term <term>long-term care pharmacy</term> means a pharmacy with a national provider identifier associated with taxonomy code 3336L0003X (or a successor code), as maintained by the National Uniform Claim Committee.</text></subclause> 
<subclause id="H511EA00E34174F9082FBE75C2DF4A5BD"><enum>(III)</enum><header>Maximum fair price</header><text>The term <term>maximum fair price</term> has the meaning given such term in section 1191(c)(3).</text></subclause> <subclause id="HAD051813E6BD489AB03815821E97EA85" commented="no"><enum>(IV)</enum><header>Maximum fair price eligible individual</header><text>The term <term>maximum fair price eligible individual</term> has the meaning given such term in section 1191(c)(2).</text></subclause> 
<subclause id="H076E57C7969B4D9196295B55406EE168"><enum>(V)</enum><header>Specified prescription</header><text>The term <term>specified prescription</term> means a covered part D drug dispensed by a long-term care pharmacy to an applicable maximum fair price eligible individual at the maximum fair price pursuant to section 1193(a)(3)(A).</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="H132866FC4FAB4E5DB116F2A2797E9D13"> <enum>(b)</enum> <header>Repayment of long-Term pharmacy supply fees</header> <text>Section 1860D–15 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-115">42 U.S.C. 1395w–115</external-xref>) is amended by adding at the end the following new subsection:</text>
        <quoted-block id="H11FC194CB98C4553BF1476C155789FBB" style="OLC">
          <subsection id="HB81D8853DFF24A0D9C1F91A7B0794635">
            <enum>(i)</enum>
            <header>Repayment of long-Term pharmacy supply fees</header>
            <paragraph id="HD4F9FF55220D4B348DA26ABC4774B0F7">
              <enum>(1)</enum>
              <header>In general</header>
 <text display-inline="yes-display-inline">In addition to amounts otherwise payable under this section to a PDP sponsor of a prescription drug plan or an MA organization offering an MA–PD plan, for plan years 2026 and 2027, the Secretary shall provide the PDP sponsor or MA organization offering the plan subsidies in an amount equal to the aggregate amount of supply fees paid by such sponsor or organization to long-term care pharmacies pursuant to section 1860D–4(b)(1)(F) during the plan year.</text>
            </paragraph>
            <paragraph id="HE57B5326EE794AC2BCB110E02BF1C7C4">
              <enum>(2)</enum>
              <header>Timing</header>
 <text>The Secretary shall provide a subsidy under paragraph (1), as applicable, not later than 18 months following the end of the applicable plan year.</text>
            </paragraph>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection> 
<subsection id="H79AA5C9A4FA943F1AF3770EFAECA4F53"><enum>(c)</enum><header>GAO study and report</header> 
<paragraph id="HEF98663B683E447F93CB52BEA0E18DB5"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 12 months after the date of enactment of this section, the Comptroller General of the United States shall complete a study and submit to Congress a report on the economic sustainability of the participation of long-term care pharmacies in the Medicare prescription drug program. Such report shall include—</text> <subparagraph id="HD677D23D671743298BD279C1E031E19F"><enum>(A)</enum><text display-inline="yes-display-inline">an analysis of—</text> 
<clause id="H947E72812DE8410B99B14956E471BD51"><enum>(i)</enum><text display-inline="yes-display-inline">payment to long-term care pharmacies under the Medicare prescription drug program with respect to—</text> <subclause id="H531E1731325C405B96E9FE53244BE4CA"><enum>(I)</enum><text>ingredient costs—</text> 
<item id="HBC13A49400D8487CA988F2CECA5287AA"><enum>(aa)</enum><text>for brand-name drugs; and</text></item> <item id="H00465664C3834A9FB4B9727C7AAC8E3F"><enum>(bb)</enum><text>for generic drugs; and</text></item></subclause> 
<subclause id="H2ECE8B76910C4FEC92B71AFC348AC2A4"><enum>(II)</enum><text>dispensing fees;</text></subclause></clause> <clause id="H2535C3F517164FBB8E7CAAC20A76B331"><enum>(ii)</enum><text>the costs to long-term care pharmacies of compliance with the performance and service criteria for network long-term care pharmacies, as described in the Medicare Prescription Drug Benefit Manual; and</text></clause> 
<clause id="H28E4100747EF4C11ABE7BC696D984AFC"><enum>(iii)</enum><text display-inline="yes-display-inline">changes to payment to long-term care pharmacies under the Medicare prescription drug program during the 5-year period preceding the date of enactment of this section; and</text></clause></subparagraph> <subparagraph id="H149C722BBD3C4B6CBA610B73C3B4DF9D"><enum>(B)</enum><text display-inline="yes-display-inline">recommendations on steps that Congress and the Secretary of Health and Human Services should consider for purposes of creating a sustainable payment system under the Medicare prescription drug program for long-term care pharmacies that would ensure that Medicare beneficiaries with long-term care needs have uninterrupted access to long-term care pharmacy services in all markets, particularly rural markets.</text></subparagraph></paragraph> 
<paragraph id="HC6AC5E80DADA431CB5E335DFCA2AB7D0"><enum>(2)</enum><header>Definitions</header><text>In this subsection:</text> <subparagraph id="H9448EAD9686C46DC912FADD0DA27F154"><enum>(A)</enum><header>Long-term care pharmacy</header><text display-inline="yes-display-inline">The term <quote>long-term care pharmacy</quote> has the meaning given such term in subparagraph (F)(iii)(II) of section 1860D–4(b)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-104">42 U.S.C. 1395w–104(b)(1)</external-xref>), as added by subsection (a).</text></subparagraph> 
<subparagraph id="H10A00FC07240424CA4ACEA38322EE9EA"><enum>(B)</enum><header>Medicare beneficiary</header><text display-inline="yes-display-inline">The term <quote>Medicare beneficiary</quote> means an individual who is entitled to benefits under part A of title XVIII of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395c">42 U.S.C. 1395c et seq.</external-xref>) or enrolled under part B of such title (<external-xref legal-doc="usc" parsable-cite="usc/42/1395j">42 U.S.C. 1395j et seq.</external-xref>).</text></subparagraph> <subparagraph id="H0C624B7C3BB74D3BA590AB1C99F7CACD"><enum>(C)</enum><header>Medicare prescription drug program</header><text>The term <quote>Medicare prescription drug program</quote> means the program under part D of title XVIII of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-101">42 U.S.C. 1395w–101 et seq.</external-xref>).</text></subparagraph></paragraph></subsection></section> 
</legis-body></bill>

